61771-79-7

Upstream product

• 54966-52-8 4-cyclohexyl-4-oxo-butyric acid ethyl ester 
• 917-54-4 methyllithium 
• 201230-82-2 carbon monoxide 
• 626-62-0 Cyclohexyl iodide 
• 78-94-4 methyl vinyl ketone 
• 133983-56-9 5-(diphenylphosphinoyl)-2-(methylthio)-1-pentene 
• 110-82-7 cyclohexane 
• 2043-61-0 cyclohexanecarbaldehyde 
• 56077-28-2 Bromomethyl cyclohexyl ketone 
• 823-76-7 Cyclohexyl methyl ketone 
• 116-11-0 2-Methoxypropene 
• 31151-40-3 2-cyclohexyl-1-diazo-2-ethanone 
• 4749-28-4 2-nitropropene 
• 119612-85-0 {[1-cyclohexylethenyl]oxy}trimethylsilane 

Downstream Products

• 80921-72-8 2-cyclohexyl-5-methyl-furan 
• 820247-70-9 1-cyclohexyl-1,4-pentanediol 
• 1193-81-3 rac-1-cyclohexylethanol 
• 823-76-7 Cyclohexyl methyl ketone 
• 1312717-71-7 ethyl 2-(2-cyclohexyl-5-methyl-1H-pyrrol-1-yl)acetate 
• 1312717-72-8 ethyl 2-(5-cyclohexyl-2-methyl-3-(2-(pyrrolidin-1-ylsulfonyl)benzyl)-1H-pyrrol-1-yl)acetate 
• 1312717-74-0 ethyl 2-(3-cyano-2-cyclohexyl-5-methyl-4-(2-(pyrrolidin-1-ylsulfonyl)benzyl)-1H-pyrrol-1-yl)acetate 
• 1312717-24-0 2-(3-cyano-2-cyclohexyl-5-methyl-4-(2-(pyrrolidin-1-ylsulfonyl)benzyl)-1H-pyrrol-1-yl)acetic acid 
• 1260147-19-0 2-cyclohexyl-1,5-dimethylpyrrole 
• 1260147-22-5 C₁₈H₂₃N 
• 1260147-06-5 C₁₈H₂₃N 
• 113020-28-3 (2S,5S)-2-Cyclohexyl-5-methyl-tetrahydro-furan 
• 113020-28-3 (2S,5R)-2-Cyclohexyl-5-methyl-tetrahydro-furan 
• 123184-34-9 3-(2-Cyclohexyl-5-methyl-pyrrol-1-yl)-propionitrile 

Relevant academic research and scientific papers

Carbonylation of Alkyl Radicals Derived from Organosilicates through Visible-Light Photoredox Catalysis

Primary, secondary, and tertiary alkyl radicals formed by the photocatalyzed oxidation of organosilicates underwent efficient carbonylation with carbon monoxide (CO) to give a variety of unsymmetrical ketones. This study introduces the possibility of radi

In vivo potent BM635 analogue with improved drug-like properties

BM635 is the hit compound of a promising anti-TB compound class. Herein we report systematic variations around the central pyrrole core of BM635 and we describe the design, synthesis, biological evaluation, pharmacokinetic analysis, as well as in vivo TB mouse efficacy studies of novel BM635 analogues that show improved physicochemical properties. This hit-to-lead campaign led to the identification of a new analogue, 4-((1-isopropyl-5-(4-isopropylphenyl)-2-methyl-1H-pyrrol-3-yl)methyl)morpholine (17), that shows excellent activity (MIC = 0.15 μM; SI = 133) against drug-sensitive Mycobacterium tuberculosis strains, as well as efficacy in a murine model of TB infection.

Direct Aldehyde Csp2?H Functionalization through Visible-Light-Mediated Photoredox Catalysis

The development of methods for carbon–carbon bond formation under benign conditions is an ongoing challenge for synthetic chemists. In recent years there has been considerable interest in using selective C?H activation as a direct route for generating rea

Atom-economical synthesis of unsymmetrical ketones through photocatalyzed C-H activation of alkanes and coupling with CO and electrophilic alkenes

A three-component coupling between alkanes, CO, and electron-deficient alkenes in the presence of a catalytic amount of (nBu4N) 4W10O32 (TBADT) has resulted in the efficient formation of unsymmetrical ketones. This process is based on the carbonylation of alkyl radicals photocatalytically generated by C-H activation of alkanes and the subsequent addition to alkenes (see scheme; EWG=electron-withdrawing group).

CRTH2 MODULATORS

Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I:

Polarity reversal induced by electrochemically generated thiazol-2-ylidenes: The Stetter reaction

The inversion of the normal reactivity (umpolung) of aldehydes has been induced via N-heterocyclic carbenes (NHCs) thiazol-2-ylidenes 2a or 3a, generated by simple electrolyses of solutions containing thiazolium salt 2 or 3. Accordingly, 1,4-dicarbonyl compounds have been obtained, in mild conditions and in moderate to very high yields, via 1,4-addition of the Breslow intermediates to the suitable Michael acceptor. The procedure has been performed in classical organic solvents (VOCs) as well as in room temperature ionic liquids (RTILs). The different reactivity of aliphatic aldehydes vs the one of aromatic and heteroaromatic aldehydes has been emphasized.

New rhodium(II) catalyzed synthesis of 1,4-dicarbonyl compounds from α-diazo ketones using vinyl ethers as two-carbon synthons

Rhodium(II) acetate catalyzed reactions of various α-diazo ketones, and vinyl ethers afforded γ-ketoaldehydes or 1,4-diketones in a facile manner. In this process, oxycyclopropanes are formed as intermediates, and are subsequently ring opened in the prese

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

The stereochemistry of the vinylogous Peterson elimination

Base-induced eliminations of the vinylogous β-hydroxysilanes 7, 9, 11 and 12 are stereospecifically syn, giving largely the trans,trans-diene 8 from 7 and 11, the cis,trans-diene 10 from 9, and the trans,cis-diene 13 from 12. When a cis double bond is produced, it is selectively placed adjacent to the carbon atom that originally carried the hydroxy group. E2′ Reactions with silyl as the electrofugal group and acetate as the nucleofugal group, initiated by fluoride ion, are not stereospecific, but can be highly stereoselective in favour of the trans,trans-diene 8 when the carbon substituent at the silicon-bearing end is a cyclohexyl group and the double bond is cis, and in favour of the trans,cis-diene 13 when the carbon substituent at the silicon-bearing end is a methyl group and the double bond is trans. Attempts to use the Peterson reactions to make o-quinodimethanes stereospecifically failed, with no evidence of 1,4-elimination from the alcohols 40 and 41. The corresponding E2′ reaction from the esters using fluoride ion on the acetates or formates 46 and 47 gave stereoselectively the E,E-quinodimethane 48.